Northern Financial Advisors Inc Trims Stock Holdings in Gilead Sciences, Inc. $GILD

Northern Financial Advisors Inc trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 50.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,512 shares of the biopharmaceutical company’s stock after selling 4,652 shares during the period. Northern Financial Advisors Inc’s holdings in Gilead Sciences were worth $554,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of GILD. Corundum Trust Company INC purchased a new stake in shares of Gilead Sciences in the third quarter worth $26,000. Financial Consulate Inc. grew its stake in shares of Gilead Sciences by 85.8% in the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 109 shares during the last quarter. MTM Investment Management LLC grew its stake in shares of Gilead Sciences by 176.0% in the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 176 shares during the last quarter. BOCHK Asset Management Ltd purchased a new stake in shares of Gilead Sciences in the fourth quarter worth $31,000. Finally, Millstone Evans Group LLC grew its stake in shares of Gilead Sciences by 58.7% in the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 118 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead completed regulatory approvals for its acquisition of Arcellx, expanding its cell?therapy oncology footprint—a strategic, long?term growth catalyst. Gilead Deepens Oncology Reach And HIV Prevention
• Positive Sentiment: Zacks publishes a bullish style/valuation thesis highlighting Gilead as a top value stock for long?term investors, reinforcing buy?and?hold narratives for value?driven funds. Why Gilead Sciences is a Top Value Stock
• Neutral Sentiment: An independent price target adjustment raised GILD’s target to $130; the change is notable but below recent trading levels, so its impact is mixed. Price Target Raised to $130
• Neutral Sentiment: Investor commentary (Seeking Alpha) outlines cautious positioning ahead of Q1 earnings—some traders consider selling into earnings volatility while longer?term holders remain anchored. Why I’m Tempted To Sell Ahead Of Q1 Earnings
• Negative Sentiment: Zacks Research trimmed its EPS forecasts across Q1–Q4 and lowered FY?2026 to $8.29 from $8.34 (consensus remains higher at ~$8.63). The cuts — though modest — reinforce near?term earnings risk and likely contributed to weaker sentiment.
• Negative Sentiment: Arcus halted a Gilead?partnered late?stage lung?cancer trial, a direct negative for oncology program timelines and near?term clinical risk exposure. Arcus halts Gilead-partnered late-stage trial
• Negative Sentiment: Market reaction: recent reports note GILD traded down (about a 1.3% decline in a recent close), reflecting the combination of analyst downgrades and clinical news pressuring the stock. Gilead Declines More Than Market

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Argus upped their price target on Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Mizuho upped their price target on Gilead Sciences from $140.00 to $170.00 and gave the company an “outperform” rating in a report on Wednesday, February 18th. Leerink Partners upped their price target on Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. Citigroup upped their price target on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a report on Monday, April 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $170.00 price target on shares of Gilead Sciences in a report on Monday, February 23rd. Twenty-four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $157.35.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total value of $463,290.00. Following the transaction, the chief financial officer owned 167,779 shares of the company’s stock, valued at $25,910,110.97. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total value of $4,324,320.00. Following the completion of the transaction, the insider directly owned 120,288 shares in the company, valued at $18,577,278.72. This trade represents a 18.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 294,280 shares of company stock valued at $42,302,950 over the last quarter. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences Stock Down 1.3%

GILD stock opened at $135.87 on Tuesday. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The business’s 50-day moving average is $144.03 and its two-hundred day moving average is $131.74. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The company has a market cap of $168.64 billion, a price-to-earnings ratio of 20.07, a P/E/G ratio of 1.82 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter in the prior year, the company earned $1.90 earnings per share. Gilead Sciences’s revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post 8.63 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were issued a $0.82 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend was Friday, March 13th. Gilead Sciences’s dividend payout ratio is currently 48.45%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.